A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.
Inclusion Criteria:
Exclusion Criteria:
Capital Federal, Buenos Aires 1015, Argentina
Capital Federal, Buenos Aires 1425, Argentina
Capital Federal, Buenos Aires 1428, Argentina
Capital Federal, Buenos Aires 1431, Argentina
Kitakyushu-shi, Fukuoka 8078555, Japan
Higashi-hiroshima-shi, Hiroshima 7390002, Japan
Kato-shi, HyĹŤgo 6731462, Japan
Sasebo-shi, Nagasaki 8571195, Japan
Tomigusuku-shi, Okinawa 9010243, Japan
Bunkyo-ku, Tokyo 1138519, Japan
Shinjuku-Ku, Tokyo 1608582, Japan
Toshima-ku, Tokyo 1708476, Japan
Panorama, Western Cape 7500, South Africa
Pinelands, Cape Town, Western Cape 7405, South Africa
Tygerberg, Western Cape 7505, South Africa